Key Stats for Danaher Stock
- Past-Week Performance: +1.1%
- 52-Week Range: $171 to $242.8
- Current Price: $189.4
What Happened?
Danaher‘s $9.9 billion acquisition of Masimo, a patient-monitoring device maker best known for hospital pulse oximeters, marks the company’s sharpest strategic pivot in years, expanding its $10 billion diagnostics franchise beyond lab tools into acute bedside care while shares sit at $189.35, well below the 52-week high of $242.8.
On February 17, Danaher agreed to pay $180 per share in cash for Masimo, a 38.3% premium, with the deal expected to close in the second half of 2026 and management projecting $0.15 to $0.2 in adjusted EPS accretion in the first full post-close year, rising to roughly $0.7 by year five.
Underpinning the deal’s financial logic, Danaher’s bioprocessing unit, which supplies the filtration, bioreactors, and purification tools that drugmakers use to manufacture biologic medicines, delivered high-single-digit core revenue growth in Q4 2025 and generated $5.3 billion in free cash flow for the full year, a 145% conversion ratio that funds the acquisition without straining a balance sheet sitting just above 2.0x EBITDA post-deal.
President and CEO Rainer Blair stated at the TD Cowen 46th Annual Healthcare Conference on March 3 that “we’ve been looking at Masimo for 10 years, maybe more,” and tied the timing to $125 million in projected cost synergies, split across manufacturing, operating expenses, and eliminated public company costs, alongside $50 million in cross-selling opportunities between Masimo’s U.S.-dominant pulse oximetry installed base and Radiometer’s stronger European footprint.
Danaher enters its Q1 2026 earnings call on April 21 with full-year adjusted EPS guidance of $8.35 to $8.5, a bioprocessing franchise management expects to grow high single digits as biologic drug revenues surpassed small molecules globally for the first time in 2025, and a Cepheid molecular diagnostics business, which runs rapid PCR tests at the point of care, adding its newly FDA-cleared 11-pathogen gastrointestinal panel to an installed base of over 60,000 instruments already primed for the company’s expanding syndromic test menu.
Wall Street’s Take on DHR Stock
The Masimo acquisition, which adds non-invasive patient monitoring to a diagnostics franchise already generating $9.9 billion in annual revenue, sharpens the EPS recovery thesis by layering $0.15 to $0.20 in year-one accretion onto a base already inflecting upward.
DHR’s normalized EPS grew 4.3% in FY 2025 to $7.80, then accelerates to an estimated $8.41 in FY 2026 (+7.8%) and $9.11 in FY 2027 (+8.3%), driven by bioprocessing consumables management guided to grow 8% to 9% in FY 2026, a $250 million cost action program delivering $0.30 in EPS benefit this year, and 35% to 40% incremental fall-through on every dollar of core revenue growth above 3%.
Meanwhile, Thermo Fisher Scientific (TMO), Danaher’s closest peer in life sciences tools and diagnostics supply, shows TIKR-estimated normalized EPS growth of 7.2% in FY 2026 to $24.52, versus Danaher’s 7.8% at $8.41, a near-identical growth rate, yet Danaher trades at a meaningful discount to Thermo Fisher’s forward multiple while carrying the additional Masimo accretion runway Thermo Fisher does not.
Conviction on the Street runs deep: 18 buys and 4 outperforms against just 3 holds and 1 no opinion among 26 analysts, with a mean price target of $264.91, implying roughly 39.9% upside from the current $189.35, as analysts price in the bioprocessing recovery and Masimo close expected in the second half of this year.
The spread between the street’s $220.00 floor and $310.00 ceiling tells the real story: the low reflects a scenario where Masimo integration disappoints and bioprocessing equipment stays flat beyond 2026, while the high assumes equipment orders accelerate from the three consecutive quarters of sequential growth already on the books.
What Does the Valuation Model Say?
The TIKR mid-case target of $297.44, implying a 9.9% annualized IRR to December 31, 2030, rests on 6.5% revenue CAGR and net income margins expanding from 22.7% in FY 2025 to 25.5% by FY 2030, assumptions directly supported by Masimo accretion, the Cepheid syndromic panel rollout across 60,000-plus installed instruments, and a bioprocessing consumables base tied to biologic drug volumes that surpassed small molecules globally for the first time in FY 2025.
The market prices DHR near a 52-week low of $171.00 on M&A skepticism, ignoring that free cash flow conversion has exceeded 100% for 34 consecutive years and FY 2026 FCF is estimated at $5.84 billion.
Bioprocessing consumables, which represent roughly 75% of commercial drug-volume-driven demand, posted high-single-digit growth in Q4 2025 and support the TIKR model’s $297.44 target through durable, prescription-volume-anchored revenue, not cyclical capital spending.
CEO Rainer Blair’s statement that even at 3% core growth Danaher delivers high-single-digit EPS growth and 100 basis points of margin expansion confirms the business has structural earnings power the current $189.35 price does not reflect.
A deceleration in bioprocessing consumables demand, which drives roughly 75% of that segment’s revenue and underpins the TIKR model’s 6.5% revenue CAGR, would compress the margin expansion path and push the $297.44 target meaningfully lower.
The April 21 Q1 2026 earnings call is the first hard data point on whether Masimo synergy execution is on track and whether bioprocessing consumables are sustaining their high-single-digit trajectory; watch the bioprocessing core growth figure against the high-single-digit benchmark.
Should You Invest in Danaher Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up DHR stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Danaher Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze DHR stock on TIKR for Free →
